What is claimed is:

1. Use of rilzabrutinib in the manufacture of a medicament for treating immune thrombocytopenia (ITP) in a patient in need thereof, wherein the medicament is to be administered to the patient in need thereof in a therapeutically effective amount, and wherein the patient in need thereof has at least one characteristic chosen from:
    a. a Z-score of ≤ -1 on the Cogstate Brief Battery (CBB) detection test (DET) relative to age-matched normative data;
    b. a Z-score of ≤ -1 on the CBB identification test (IDN) relative to age-matched normative data;
    c. a Z-score of ≤ -1 for composite DET and IDN scores relative to age-matched normative data;
    d. a Z-score of ≤ -1 on the CBB one card learning test (OCL) relative to age-matched normative data;
    e. a Z-score of ≤ -1 on the CBB one back test (ONB) relative to age-matched normative data; and
    f. a Z-score of ≤ -1 for composite OCL and ONB scores relative to age-matched normative data.
2. Use of rilzabrutinib in the manufacture of a medicament for treating immune thrombocytopenia (ITP) in a patient in need thereof, wherein the medicament is to be administered to the patient in need thereof in a therapeutically effective amount, and wherein the patient in need thereof has at least two characteristics chosen from:
    a. a Z-score of ≤ -1 on the Cogstate Brief Battery (CBB) detection test (DET) relative to age-matched normative data;
    b. a Z-score of ≤ -1 on the CBB identification test (IDN) relative to age-matched normative data;
    c. a Z-score of ≤ -1 for composite DET and IDN scores relative to age-matched normative data;
    d. a Z-score of ≤ -1 on the CBB one card learning test (OCL) relative to age-matched normative data;
    e. a Z-score of ≤ -1 on the CBB one back test (ONB) relative to age-matched normative data; and
    f. a Z-score of ≤ -1 for composite OCL and ONB scores relative to age-matched normative data.

3. The use of claim 1 or 2, wherein at least one of the following occurs:
    a. the patient in need thereof has a Z-score of < -2 on the DET relative to age-matched normative data;
    b. the patient in need thereof has a Z-score of <-3 on the DET relative to age-matched normative data;
    c. the patient in need thereof has a Z-score of < -2 on the IDN relative to age-matched normative data;
    d. the patient in need thereof has a Z-score of <-3 on the IDN relative to age-matched normative data;
    e. the patient in need thereof has a Z-score of < -2 for composite DET and IDN scores relative to age-matched normative data;
    f. the patient in need thereof has a Z-score of < -3 for composite DET and IDN scores relative to age-matched normative data;
    g. the patient in need thereof has a Z-score of < -2 on the OCL relative to age-matched normative data;
    h. the patient in need thereof has a Z-score of <-3 on the OCL relative to age-matched normative data;
    i. the patient in need thereof has a Z-score of < -2 on the ONB relative to age-matched normative data;
    j. the patient in need thereof has a Z-score of <-3 on the ONB relative to age-matched normative data.
    k. the patient in need thereof has a Z-score of < -2 for composite OCL and ONB scores relative to age-matched normative data; and
    l. the patient in need thereof has a Z-score of < -3 for composite OCL and ONB scores relative to age-matched normative data.
4. The use of any one of claims 1-3, wherein at least one of the following occurs:
    a. the patient in need thereof has a platelet count of count <33,000/μL on two occasions no less than 7 days apart in the 15 days prior to beginning study treatment;
    b. the patient in need thereof has a history of response (two or more platelet counts ≥50,000/μL with an increase of ≥20,000/μL) to at least one prior line of therapy;
    c. the patient in need thereof has a history of response (two or more platelet counts ≥50,000/μL with an increase of ≥20,000/μL) to at least one prior line of therapy

chosen from a splenectomy, intravenous immunoglobin (IVIG), corticosteroids, anti-D immunoglobulin therapy, and immunosuppressive drugs; and

d. the patient in need thereof has had ITP for three or more years.

5. The use of any one of claims 1-4, wherein the baseline platelet count is the mean of two platelet counts taken on two occasions no less than 7 days apart in the 15 days prior to beginning treatment and a third count taken on the first day of the study and at least one of the following occurs:

a. the patient in need thereof achieves at least one platelet count of at least 20,000/μL above the baseline platelet count;

b. the patient in need thereof achieves at least two platelet counts of at least 20,000/μL above the baseline platelet count.

c. the patient in need thereof achieves at least two consecutive platelet counts of at least 20,000/μL above the baseline platelet count.

d. the patient in need thereof achieves at least two platelet counts of at least 20,000/μL above the baseline platelet count separated by at least five days or separated by seven days; and

e. the patient in need thereof achieves at least two consecutive platelet counts of at least 20,000/μL above the baseline platelet count separated by at least five days or separated by seven days.

6. The use of any one of claims 1-5, wherein at least one of the following occurs:

a. the patient in need thereof achieves a platelet count of at least 50,000/μL

b. the patient in need thereof achieves at least two platelet counts of at least 50,000/μL;

c. the patient in need thereof achieves at least two consecutive platelet counts of at least 50,000/μL;

d. the patient in need thereof achieves at least two platelet counts of at least 50,000/μL separated by at least five days or separated by seven days;

e. the patient in need thereof achieves at least two consecutive platelet counts of at least 50,000/μL separated by at least five days or separated by seven days;

f. the patient in need thereof achieves at least one platelet count of at least 50,000/μL within eight days of initiating treatment;

g. the patient in need thereof does not receive rescue medication during the four weeks prior to the most recent platelet count of at least 50,000/μL;

h. the patient in need thereof has platelet counts between 2,000/μL and 33,000/μL on two occasions no less than 7 days apart and within 15 days prior to the start of the treatment period.

i. the patient in need thereof has platelet counts ≤15,000/μ L on two occasions no less than 7 days apart and within 15 days prior to the start of the treatment period; and

j. the patient in need thereof has platelet counts >15,000/μL on two occasions no less than 7 days apart and within 15 days prior to the start of the treatment period.

7. The use of any one of claims 1-6, wherein at least one of the following occurs:

a. the patient in need thereof has a history of response to at least one prior therapy, wherein at least one prior therapy is chosen from a splenectomy, intravenous immunoglobin (IVIG), corticosteroids, anti-D immunoglobulin therapy, immunosuppressive drugs, TPO-RAs, and rituximab;

b. the patient in need thereof had a splenectomy prior to the start of the treatment period;

c. the patient in need thereof has a history of taking at least one prior therapy prior to the start of the treatment period;

d. the patient in need thereof has a history of taking intravenous immunoglobin (IVIG) prior to the start of the treatment period;

e. the patient in need thereof has a history of taking corticosteroids prior to the start of the treatment period;

f. the patient in need thereof has a history of taking anti-D immunoglobulin therapy prior to the start of the treatment period;

g. the patient in need thereof has a history of taking at least one immunosuppressive drug prior to the start of the treatment period;

h. the patient in need thereof has a history of taking at least one immunosuppressive drug is selected from fostamatinib, mycophenolate mofetil (MMF), and cyclosporine prior to the start of the treatment period;

i. the patient in need thereof has a history of taking at least one TPO-RA prior to the start of the treatment period;

j. the patient in need thereof has a history of taking at least one TPO-RA selected from rTPO, romiplostim, eltrombopag, and avatrombopag prior to the start of the treatment period; and

k. the patient in need thereof has a history of taking rituximab prior to the start of the treatment period.

8. The use of claim 7, wherein the response to the prior therapy comprised a platelet count of ≥50,000/μL.

9. The use of any one of claims 1-8, wherein the patient in need thereof is to be administered at least one TPO-RA or wherein the patient in need thereof is to be administered at least one TPO-RA is selected from rTPO, romiplostim, eltrombopag, and avatrombopag.

10. The use of any one of claims 1-9, wherein at least one of the following occurs:
    a. the patient in need thereof has primary ITP;
    b. the patient in need thereof has secondary ITP;
    c. the patient in need thereof does not have chronic ITP;
    d. the patient in need thereof has persistent ITP;
    e. the patient in need thereof has chronic ITP;
    f. the patient in need thereof has relapsing ITP; and
    g. the patient in need thereof has refractory ITP.

11. The use of any one of claims 1-10, wherein the treatment period is at least 8 days, at least 28 days, at least 84 days, or at least 169 days.

12. The use of any one of claims 1-11, wherein:
    a. the patient in need thereof is to be administered 400 mg of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof twice a day; and/or
    b. the patient in need thereof is to be administered 400 mg of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof twice a day; and
        i. the at least one compound consists of at least one compound chosen from the (E) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof; or
        ii. the at least one compound consists of at least one compound chosen from the (Z) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-

d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile and pharmaceutically acceptable salts thereof; or

iii. the at least one compound consists of a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile or a pharmaceutically acceptable salt of the foregoing.

13. The use of any one of claims 1-11, wherein

a. the patient in need thereof is to be administered 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile twice a day; and/or

b. the patient in need thereof is to be administered 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile twice a day; and

i. the at least one compound is the (E) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; or

ii. the at least one compound is the (Z) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; or

iii. the at least one compound consists of a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

14. The use of any one of claims 1-13, wherein:

a. the medicament is to be orally administered to the patient in need thereof;

b. the medicament is to be administered to the patient in need thereof in the form of at least one tablet; and/or

c. the medicament is to be administered to the patient in need thereof with water.